Overview |
bs-20743R-BF680 |
5HT2A Receptor Polyclonal Antibody, AbBy Fluor® 680 Conjugated |
IF(ICC) |
Human, Mouse, Rat |
Specifications |
AbBy Fluor® 680 |
Rabbit |
KLH conjugated synthetic peptide derived from human 5HT2A Receptor |
21-120/471 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
3356 |
P28223 |
Cell membrane |
5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor; Serotonin receptor 2A; 5-HT-2A; 5-HT-2; HTR2A; Htr2a; 5 HT 2; 5HTR2A; 5 HT 2A; 5 HT2 receptor; 5 HT2A; 5 hydroxytryptamine receptor 2A; 5-HT-2; 5-HT-2A; 5-hydroxytryptamine 2A receptor; 5-hydroxytryptamine receptor 2A; 5HT2A_HUMAN; HTR 2; HTR 2A; HTR2; HTR2A |
G-protein coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:1330647, PubMed:18703043, PubMed:19057895). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) (PubMed:28129538). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors (PubMed:28129538). Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways (PubMed:28129538). Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca2+ ions from intracellular stores (PubMed:18703043, PubMed:28129538). Affects neural activity, perception, cognition and mood (PubMed:18297054). Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction. |
Application Dilution |
IF(ICC) |
1:50-200 |